As of August 29, 2026, Intellia Therapeutics's top three insider holders are Fred E Cohen (Director, 207.45K shares), James Basta (Evp, General Counsel, 156.79K shares), Edward J Iii Dulac (Evp, Chief Financial Officer, 156.29K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Fred E Cohen | Director | 207,453 | 0 | 207,453 | 13.7% | 07 Jan, 2026 |
| 2 | James Basta | Evp, General Counsel | 156,794 | 0 | 156,794 | 10.4% | 03 Mar, 2026 |
| 3 | Edward J Iii Dulac | Evp, Chief Financial Officer | 156,286 | 0 | 156,286 | 10.3% | 06 Jul, 2026 |
| 4 | William J Chase | Director | 143,893 | 0 | 143,893 | 9.5% | 10 Jun, 2026 |
| 5 | Birgit C Schultes | Evp, Chief Scientific Officer | 137,733 | 0 | 137,733 | 9.1% | 03 Mar, 2026 |
| 6 | David Lebwohl | Evp, Chief Medical Officer | 131,192 | 0 | 131,192 | 8.7% | 03 Mar, 2026 |
| 7 | Eliana Clark | Evp, Chief Technical Officer | 93,864 | 0 | 93,864 | 6.2% | 03 Mar, 2026 |
| 8 | Laura Sepp-Lorenzino | Evp, Chief Scientific Officer | 77,388 | 0 | 77,388 | 5.1% | 07 Jan, 2025 |
| 9 | Glenn Goddard | Evp, Chief Financial Officer | 69,213 | 0 | 69,213 | 4.6% | 05 Mar, 2024 |
| 10 | Michael P Dube | Vp, Chief Accounting Officer | 66,886 | 0 | 66,886 | 4.4% | 06 Jul, 2026 |
| 11 | Derek Hicks | Evp, Chief Business Officer | 59,878 | 0 | 59,878 | 4.0% | 07 Jan, 2025 |
| 12 | Georgia Keresty | Director | 41,083 | 0 | 41,083 | 2.7% | 10 Jun, 2026 |
| 13 | Muna Bhanji | Director | 36,403 | 0 | 36,403 | 2.4% | 10 Jun, 2026 |
| 14 | Frank Verwiel | Director | 35,148 | 0 | 35,148 | 2.3% | 10 Jun, 2026 |
| 15 | Jesse Goodman | Director | 33,559 | 0 | 33,559 | 2.2% | 10 Jun, 2026 |
| 16 | Brian Goff | Director | 32,609 | 0 | 32,609 | 2.2% | 10 Jun, 2026 |
| 17 | Caroline Dorsa | Director | 12,701 | 0 | 12,701 | 0.8% | 16 Jun, 2022 |
| 18 | John F Crowley | Director | 11,716 | 0 | 11,716 | 0.8% | 16 Jun, 2023 |
| 19 | Jean Francois Formela | Director | 7,291 | 0 | 7,291 | 0.5% | 16 Jun, 2022 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 01 Jul, 2026 | Michael P Dube | Vp, Chief Accounting Officer | Disposed S | 2,641 | $16.78 | $44.32K | 66,886 | Direct |
| 02 Jul, 2026 | Edward J Iii Dulac | Evp, Chief Financial Officer | Disposed S | 4,677 | $18.00 | $84.19K | 156,286 | Direct |
| 09 Jun, 2026 | Brian Goff | Director | Acquired A | 9,200 | $0.00 | $0 | 32,609 | Direct |
| 09 Jun, 2026 | Frank Verwiel | Director | Acquired A | 9,200 | $0.00 | $0 | 35,148 | Direct |
| 09 Jun, 2026 | William J Chase | Director | Acquired A | 9,200 | $0.00 | $0 | 143,893 | Direct |
| 09 Jun, 2026 | Georgia Keresty | Director | Acquired A | 9,200 | $0.00 | $0 | 41,083 | Direct |
| 09 Jun, 2026 | Muna Bhanji | Director | Acquired A | 9,200 | $0.00 | $0 | 36,403 | Direct |
| 09 Jun, 2026 | Jesse Goodman | Director | Acquired A | 9,200 | $0.00 | $0 | 33,559 | Direct |
| 09 Jun, 2026 | Jesse Goodman | Director | Acquired A | 13,300 | $0.00 | $0 | 13,300 | Direct |
| 09 Jun, 2026 | Muna Bhanji | Director | Acquired A | 13,300 | $0.00 | $0 | 13,300 | Direct |
| 09 Jun, 2026 | Frank Verwiel | Director | Acquired A | 13,300 | $0.00 | $0 | 13,300 | Direct |
| 09 Jun, 2026 | Georgia Keresty | Director | Acquired A | 13,300 | $0.00 | $0 | 13,300 | Direct |
| 09 Jun, 2026 | Brian Goff | Director | Acquired A | 13,300 | $0.00 | $0 | 13,300 | Direct |
| 09 Jun, 2026 | William J Chase | Director | Acquired A | 13,300 | $0.00 | $0 | 13,300 | Direct |
| 01 Mar, 2026 | David Lebwohl | Evp, Chief Medical Officer | Acquired A | 9,943 | $0.00 | $0 | 131,192 | Direct |
| 01 Mar, 2026 | Birgit C Schultes | Evp, Chief Scientific Officer | Acquired A | 39,200 | $0.00 | $0 | 137,733 | Direct |
| 01 Mar, 2026 | Birgit C Schultes | Evp, Chief Scientific Officer | Acquired A | 39,200 | $0.00 | $0 | 137,733 | Direct |
| 01 Mar, 2026 | Birgit C Schultes | Evp, Chief Scientific Officer | Acquired A | 39,200 | $0.00 | $0 | 137,733 | Direct |
| 01 Mar, 2026 | David Lebwohl | Evp, Chief Medical Officer | Acquired A | 9,943 | $0.00 | $0 | 131,192 | Direct |
| 01 Mar, 2026 | James Basta | Evp, General Counsel | Acquired A | 46,080 | $0.00 | $0 | 158,005 | Direct |